Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Lele

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|April 1, 1989
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinomaS B Lele, M S Piver
Journal of Surgical Oncology|May 1, 1986
Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinomaJ J Barlow, S B Lele
Obstetrics and Gynecology|September 1, 1986
Interval laparoscopy as predictor of response to chemotherapy in ovarian carcinomaS B Lele, M S Piver
Cancer Treatment Reports|December 1, 1984
Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinomaJ J Barlow, S B Lele
Obstetrics and Gynecology|September 1, 1984
Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavageM S Piver, S B Lele, B Patsner
European Journal of Gynaecological Oncology|January 1, 1988
Malignant peritoneal cytology in stage I endometrial adenocarcinoma: the effect of progesterone therapy (a preliminary report)M S Piver, S B Lele, M Gamarra
American Journal of Clinical Oncology|February 1, 1987
Cisplatin plus VP16-213 in refractory ovarian carcinomaS B Lele, M S Piver, J Malfetano
Gynecologic Oncology|March 1, 1986
cis-Diamminedichloroplatinum plus dimethyl-triazenoimidazole carboxamide as second- and third-line chemotherapy for sarcomas of the female pelvisM S Piver, S B Lele, B Patsner
American Journal of Obstetrics and Gynecology|June 1, 1985
Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resectionJ J Barlow, S B Lele, L J Emrich
Obstetrics and Gynecology|July 1, 1978
Incidence of subclinical metastasis in stage I and II ovarian carcinomaM S Piver, J J Barlow, S B Lele
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|April 1, 1989
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinomaS B Lele, M S Piver
Journal of Surgical Oncology|May 1, 1986
Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinomaJ J Barlow, S B Lele
Obstetrics and Gynecology|September 1, 1986
Interval laparoscopy as predictor of response to chemotherapy in ovarian carcinomaS B Lele, M S Piver
Cancer Treatment Reports|December 1, 1984
Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinomaJ J Barlow, S B Lele
Obstetrics and Gynecology|September 1, 1984
Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavageM S Piver, S B Lele, B Patsner
European Journal of Gynaecological Oncology|January 1, 1988
Malignant peritoneal cytology in stage I endometrial adenocarcinoma: the effect of progesterone therapy (a preliminary report)M S Piver, S B Lele, M Gamarra
American Journal of Clinical Oncology|February 1, 1987
Cisplatin plus VP16-213 in refractory ovarian carcinomaS B Lele, M S Piver, J Malfetano
Gynecologic Oncology|March 1, 1986
cis-Diamminedichloroplatinum plus dimethyl-triazenoimidazole carboxamide as second- and third-line chemotherapy for sarcomas of the female pelvisM S Piver, S B Lele, B Patsner
American Journal of Obstetrics and Gynecology|June 1, 1985
Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resectionJ J Barlow, S B Lele, L J Emrich
Obstetrics and Gynecology|July 1, 1978
Incidence of subclinical metastasis in stage I and II ovarian carcinomaM S Piver, J J Barlow, S B Lele
Pageof 5